X
<

Where Is Novartis Positioned after 3Q17?

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 12
Where Is Novartis Positioned after 3Q17? PART 12 OF 12

Novartis on the Street: Analysts’ Recommendations in November

Recent regulatory submissions

In November 2017, Novartis (NVS) submitted a Marketing Authorization Application (or MAA) to the European Medical Agency (or EMA) for Kymriah (tisagenlecleucel) or CTL019 as a treatment for adult individuals with relapsed or refractory DLBCL (diffuse large B-cell lymphoma) who are not eligible for autologous stem cell transplant (or ASCT).

Novartis also submitted an MAA for CTL019 as a treatment for individuals aged under 25 years old with relapsed or refractory B-cell acute lymphoblastic leukemia (or ALL).

Novartis on the Street: Analysts’ Recommendations in November

Interested in NVS? Don't miss the next report.

Receive e-mail alerts for new research on NVS

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Analyst recommendations

Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold.” On November 13, 2017, Novartis had a consensus 12-month consensus target price of $93.00, which represents a ~12.1% return on investment over the next 12 months.

Notably, the Vanguard FTSE Europe ETF (VGK) invests ~1.2% of its total portfolio holdings in Novartis.

Competitor ratings

Of the 22 analysts tracking Pfizer (PFE) in November 2017, ~55% recommend some form of “buy.” On November 13, 2017, Pfizer had a consensus 12-month target price of $38.47, which represents a ~9.4% return on investment over the next 12 months.

Of the 20 analysts tracking Merck (MRK) in November 2017, ~50% recommend a “buy.” On November 13, 2017, Merck had a consensus 12-month target price of ~$65.95, which represents a 19.3% return on investment over the next 12 months.

Of the 22 analysts tracking Bristol-Myers Squibb (BMY) in November 2017, ~41% recommend some form of “buy.” Two analysts recommend a “sell” for the stock. On November 13, 2017, Bristol-Myers Squibb had a 12-month consensus target price of $63.24, which represents a ~3.9% return on investment over the next 12 months.

X

Please select a profession that best describes you: